Moderna's stock has soared 545% year-to-date, driven by its mRNA technology and a promising oncology pipeline including a personalized cancer vaccine. The company now joins the NASDAQ 100, increasing its visibility and institutional interest. Despite strong gains, investors must weigh locking in profits against the risks and potential of Moderna's developing treatments. The stock's rapid rise outpaces peers like BioNTech and Pfizer, highlighting the need for careful portfolio management.
As of Oct 07, 2026 02:21 WIB, Moderna (MRNA) trades at USD 189.95, close to its 52-week high of USD 203.46 but down 6.53% on the day, contrasting with Pfizer (PFE) which is near its 52-week high at USD 27.48 and up 0.26%. BioNTech (BNTX) remains below its 52-week peak at USD 96.22, down 1.45%, while Moderna's market cap of $81.13B is significantly smaller than Pfizer's $156.23B. On Pluang, Moderna sees a strong buy interest at 76%, compared to Pfizer's 29% buy activity.
Vaccine stocks surged after a Siberian plague scare, but health officials have since declared the risk low, causing Novavax shares to drop 2% after a prior 20% spike. Novavax's rally was driven by speculation of government vaccine purchases, but the ...
Novavax shares surged 22% following Sanofi's rollout of the Nuvaxovid COVID-19 vaccine for the fall season, giving Novavax a commercial boost through its licensing deal. Unlike Moderna and BioNTech, Novavax earns royalties from Sanofi's sales rather ...
Moderna shares surged 8% to $204.60 as investors anticipate the full Phase 3 melanoma vaccine trial data to be presented at the European Society for Medical Oncology (ESMO) congress in Madrid. The vaccine, developed with Merck, showed promising resul...
In September, technology stocks led the S&P 500's best performers, with 13 of the top 20 winners coming from the sector. Everpure topped the list with a 40.7% gain, followed by Moderna, Intel, and Bloom Energy, each rising over 30%. On the downside, ...
Nike reported a 4% decline in Q1 sales, driven by a 22% drop in China revenue, impacting its overall performance and leading to a 9% premarket share decline. Moderna will replace Warner Bros Discovery in the Nasdaq-100, reflecting its strong market p...
